Q-omics provides the consensus-scored SMIM15P2 profile across patient tissues and cancer cell-line models. SMIM15P2 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in CESC. Among the 18 cancer types available for tumor–normal comparison, SMIM15P2 is differentially expressed in 9, with the highest sampling consensus in HNSC. Additionally, SMIM15P2 RNA expression shows 13,937 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight CESC, HNSC, and THYM as cancer lineages where SMIM15P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SMIM15P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SMIM15P2 survival associations across molecular data types. SMIM15P2 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SMIM15P2 RNA expression–survival associations across cancer types. High SMIM15P2 expression shows unfavorable associations in CESC, ESCA and HNSC, but favorable associations in LAML, STAD and LUAD. The CESC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify CESC as the clearest survival context for SMIM15P2 RNA expression.
This table summarizes SMIM15P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for SMIM15P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SMIM15P2 shows lower tumor expression in THCA and COAD and higher tumor expression in HNSC, LIHC, KIRC and READ. The HNSC box plot shows higher SMIM15P2 RNA expression in tumor versus normal tissue (log2 FC = +0.685, t-test p < 0.001).
This table shows molecular features associated with SMIM15P2 in patient tissues and cancer cell lines. In patient samples, SMIM15P2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
